Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRADA II study of atazanavir + dolutegravir + lamivudine maintenance therapy in suppressed HIV infection
NL-OMON42090Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atazanavir, dolutegravir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by Radboud University Medical Center. Primary endpoints: Atazanavir pharmacokinetics, Dolutegravir pharmacokinetics and 1 more. Started Sep 2015; status: active, not recruiting.
02
Drugs
atazanavirdolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON42090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42090.